Management of chronic Pseudomonas aeruginosa infection with inhaled levofloxacin in people with cystic fibrosis

J Stuart Elborn*, Patrick A Flume, Donald R Van Devanter, Claudio Procaccianti

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

5 Citations (Scopus)
68 Downloads (Pure)

Abstract

People with cystic fibrosis (CF) are highly susceptible to bacterial infections of the airways. By adulthood, chronic Pseudomonas aeruginosa (Pa) is the most prevalent infective organism and is difficult to eradicate owing to its adaptation to the CF lung microenvironment. Long-term suppressive treatment with inhaled antimicrobials is the standard care for reducing exacerbation frequency, improving quality of life and increasing measures of lung function. Levofloxacin (a fluoroquinolone antimicrobial) has been approved as an inhaled solution in Europe and Canada, for the treatment of adults with CF with chronic P. aeruginosa pulmonary infections. Here, we review the clinical principles relating to the use of inhaled antimicrobials and inhaled levofloxacin for the management of P. aeruginosa infections in patients with CF.

Original languageEnglish
Pages (from-to)1087–1104
Number of pages18
JournalFuture microbiology
Volume16
Issue number14
Early online date13 Aug 2021
DOIs
Publication statusPublished - Sept 2021

Keywords

  • antimicrobials
  • levofloxacin
  • levofloxacin inhaled suspension
  • Pseudomonas aeruginosa
  • fluoroquinolone
  • cystic fibrosis

Fingerprint

Dive into the research topics of 'Management of chronic Pseudomonas aeruginosa infection with inhaled levofloxacin in people with cystic fibrosis'. Together they form a unique fingerprint.

Cite this